Given the common nature of HPV,1 it is likely that patients who have ever been sexually active have been infected with cervical HPV. Because most HPV infections are asymptomatic and clear within 1-2 years of acquisition, just knowing a patient’s HPV status is of limited clinical value.
No FDA-approved HPV test is designed to detect all HPV infections. All FDA-approved HPV tests have a cut-off, and are designed to detect HPV infections that are clinically relevant and properly identify women at risk of developing cervical disease. The Aptima HPV test has shown no statistical difference in sensitivity when compared to DNA-based HPV tests.